Chemed Corporation (CHE)

Chemed presents a compelling convergence of strong fundamentals and aggressive short-term speculation. The business is fundamentally robust, boasting a 27% return on equity, nearly 44% earnings growth, and a clean balance sheet with manageable debt relative to its cash generation. The stock has delivered exceptional long-term performance, rising nearly 250% over the last nine years, though it recently faced a sharp correction following an earnings miss. Despite this dip, the valuation remains attractive with a forward P/E of roughly 19x, implying the market is pricing in a slower growth trajectory than the company's recent track record suggests. The short-term outlook is bullish despite the recent volatility. Technical indicators show the stock reclaiming key moving averages, and the recent price action suggests buyers are stepping in at these levels. However, the options market tells a cautionary tale: traders are heavily loaded with put options, creating a dense layer of resistance that could dampen immediate upside momentum. This heavy put positioning likely reflects the recent earnings miss and the fear of further downside, yet the underlying business quality remains pristine. For the long-term investor, this looks like a high-conviction buy. The company operates in a defensive healthcare sector with sticky demand, and the recent price decline offers an opportunity to acquire a compounder at a reasonable multiple. While the dividend yield is modest, the payout ratio is incredibly safe at just 12%, providing ample room for future increases. The tension between the heavy speculative put buying and the solid fundamental recovery thesis creates a volatile but ultimately favorable setup for patient capital.